Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 34 |
| List of Tables | 30 | 5 |
| List of Figures | 35 | 1 |
| Introduction | 36 | 1 |
| Global Markets Direct Report Coverage | 36 | 1 |
| Gastric Cancer Overview | 37 | 1 |
| Therapeutics Development | 38 | 2 |
| Pipeline Products for Gastric Cancer Overview | 38 | 1 |
| Pipeline Products for Gastric Cancer Comparative Analysis | 39 | 1 |
| Gastric Cancer Therapeutics under Development by Companies | 40 | 11 |
| Gastric Cancer Therapeutics under Investigation by Universities/Institutes | 51 | 1 |
| Gastric Cancer Pipeline Products Glance | 52 | 4 |
| Late Stage Products | 52 | 1 |
| Clinical Stage Products | 53 | 1 |
| Early Stage Products | 54 | 1 |
| Unknown Stage Products | 55 | 1 |
| Gastric Cancer Products under Development by Companies | 56 | 16 |
| Gastric Cancer Products under Investigation by Universities/Institutes | 72 | 1 |
| Gastric Cancer Companies Involved in Therapeutics Development | 73 | 138 |
| 3SBio Inc. | 73 | 1 |
| AB Science SA | 74 | 1 |
| AbbVie Inc | 75 | 1 |
| AbGenomics International, Inc. | 76 | 1 |
| ADC Therapeutics Sarl | 77 | 1 |
| Advaxis, Inc. | 78 | 1 |
| Advenchen Laboratories, LLC | 79 | 1 |
| Agenus, Inc. | 80 | 1 |
| Almac Discovery Limited | 81 | 1 |
| Alteogen Inc. | 82 | 1 |
| Ambrx, Inc. | 83 | 1 |
| Amgen Inc. | 84 | 1 |
| arGEN-X BV | 85 | 1 |
| Asana BioSciences, LLC | 86 | 1 |
| Aslan Pharmaceuticals Pte Ltd | 87 | 1 |
| Astellas Pharma Inc. | 88 | 1 |
| AstraZeneca Plc | 89 | 1 |
| Atara Biotherapeutics, Inc. | 90 | 1 |
| Athenex, Inc. | 91 | 1 |
| Azaya Therapeutics, Inc. | 92 | 1 |
| Basilea Pharmaceutica Ltd. | 93 | 1 |
| Bayer AG | 94 | 1 |
| BeiGene, Ltd. | 95 | 1 |
| Betta Pharmaceuticals Co. Ltd. | 96 | 1 |
| Bionovis SA | 97 | 1 |
| Boehringer Ingelheim GmbH | 98 | 1 |
| Boston Biomedical, Inc. | 99 | 1 |
| Bristol-Myers Squibb Company | 100 | 1 |
| Calithera Biosciences, Inc. | 101 | 1 |
| Cancer Prevention Pharmaceuticals, Inc. | 102 | 1 |
| Celgene Corporation | 103 | 1 |
| Celldex Therapeutics, Inc. | 104 | 1 |
| Cellectar Biosciences, Inc. | 105 | 1 |
| Celltrion, Inc. | 106 | 1 |
| Celon Pharma Sp. z o.o. | 107 | 1 |
| Cerulean Pharma, Inc. | 108 | 1 |
| Chipscreen Biosciences Ltd | 109 | 1 |
| Curaxys, S.L. | 110 | 1 |
| DAE HWA Pharmaceutical Co., Ltd. | 111 | 1 |
| Daiichi Sankyo Company, Limited | 112 | 1 |
| Debiopharm International SA | 113 | 1 |
| Deciphera Pharmaceuticals, LLC | 114 | 1 |
| Dong-A Socio Holdings Co. Ltd. | 115 | 1 |
| Dr. Reddy's Laboratories Limited | 116 | 1 |
| Eddingpharm | 117 | 1 |
| EirGenix Inc. | 118 | 1 |
| Eli Lilly and Company | 119 | 1 |
| Esperance Pharmaceuticals, Inc. | 120 | 1 |
| F. Hoffmann-La Roche Ltd. | 121 | 1 |
| Five Prime Therapeutics, Inc. | 122 | 1 |
| Frost Biologic, Inc. | 123 | 1 |
| Galena Biopharma, Inc. | 124 | 1 |
| Genelux Corporation | 125 | 1 |
| Genentech, Inc. | 126 | 1 |
| Gilead Sciences, Inc. | 127 | 1 |
| GlaxoSmithKline Plc | 128 | 1 |
| GlycoNex Inc. | 129 | 1 |
| Glycotope GmbH | 130 | 1 |
| Green Cross Corporation | 131 | 1 |
| Halozyme Therapeutics, Inc. | 132 | 1 |
| Hanmi Pharmaceuticals, Co. Ltd. | 133 | 1 |
| Horizon Pharma Plc | 134 | 1 |
| Hutchison MediPharma Limited | 135 | 1 |
| Ignyta, Inc. | 136 | 1 |
| Immunomedics, Inc. | 137 | 1 |
| Imugene Limited | 138 | 1 |
| Incyte Corporation | 139 | 1 |
| Inovio Pharmaceuticals, Inc. | 140 | 1 |
| INSYS Therapeutics, Inc. | 141 | 1 |
| Intezyne Technologies, Inc. | 142 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 143 | 1 |
| Jiangsu Kanion Pharmaceutical Co., Ltd. | 144 | 1 |
| Johnson &Johnson | 145 | 1 |
| KaloBios Pharmaceuticals, Inc. | 146 | 1 |
| Karyopharm Therapeutics, Inc. | 147 | 1 |
| Kolltan Pharmaceuticals, Inc. | 148 | 1 |
| Kuhnil Pharmaceutical Co., Ltd. | 149 | 1 |
| Kyowa Hakko Kirin Co., Ltd. | 150 | 1 |
| LegoChem Biosciences, Inc | 151 | 1 |
| Les Laboratoires Servier SAS | 152 | 1 |
| MacroGenics, Inc. | 153 | 1 |
| MaxiVAX SA | 154 | 1 |
| Mebiopharm Co., Ltd. | 155 | 1 |
| MedImmune, LLC | 156 | 1 |
| Medivation, Inc. | 157 | 1 |
| Merck &Co., Inc. | 158 | 1 |
| Merck KGaA | 159 | 1 |
| Merrimack Pharmaceuticals, Inc. | 160 | 1 |
| Mersana Therapeutics, Inc. | 161 | 1 |
| Merus NV | 162 | 1 |
| Millennium Pharmaceuticals Inc | 163 | 1 |
| Mirna Therapeutics, Inc. | 164 | 1 |
| Molecular Targeting Technologies, Inc. | 165 | 1 |
| MolMed S.p.A. | 166 | 1 |
| NanoCarrier Co., Ltd. | 167 | 1 |
| NeuClone Pty Ltd | 168 | 1 |
| Novartis AG | 169 | 1 |
| OBI Pharma, Inc. | 170 | 1 |
| Omnitura Therapeutics Inc. | 171 | 1 |
| Oncobiologics, Inc. | 172 | 1 |
| Oncolys BioPharma Inc | 173 | 1 |
| Oncolytics Biotech Inc. | 174 | 1 |
| OncoMed Pharmaceuticals, Inc. | 175 | 1 |
| OncoTherapy Science, Inc. | 176 | 1 |
| Ono Pharmaceutical Co., Ltd. | 177 | 1 |
| Opsona Therapeutics Limited | 178 | 1 |
| Panacea Biotec Limited | 179 | 1 |
| Patrys Limited | 180 | 1 |
| Pfizer Inc. | 181 | 1 |
| Pharma Mar, S.A. | 182 | 1 |
| Puma Biotechnology, Inc. | 183 | 1 |
| Rexahn Pharmaceuticals, Inc. | 184 | 1 |
| Rgenix, Inc. | 185 | 1 |
| Rhizen Pharmaceuticals S.A. | 186 | 1 |
| Richter Gedeon Nyrt. | 187 | 1 |
| Samumed LLC | 188 | 1 |
| Sanofi | 189 | 1 |
| Sequella, Inc. | 190 | 1 |
| Shanghai Henlius Biotech Co., Ltd. | 191 | 1 |
| Shionogi &Co., Ltd. | 192 | 1 |
| Simcere Pharmaceutical Group | 193 | 1 |
| Sorrento Therapeutics, Inc. | 194 | 1 |
| Spectrum Pharmaceuticals, Inc. | 195 | 1 |
| Supratek Pharma Inc. | 196 | 1 |
| SynCore Biotechnology Co., Ltd. | 197 | 1 |
| Synovo GmbH | 198 | 1 |
| Synthon Holdings BV | 199 | 1 |
| Taiho Pharmaceutical Co., Ltd. | 200 | 1 |
| Taiwan Liposome Company, Ltd. | 201 | 1 |
| Takeda Pharmaceutical Company Limited | 202 | 1 |
| Takis S.r.l. | 203 | 1 |
| Tara Immuno-Oncology Therapeutics LLC | 204 | 1 |
| Tessa Therapeutics Pte Ltd | 205 | 1 |
| Transgene SA | 206 | 1 |
| United BioPharma, Inc. | 207 | 1 |
| Vaxon Biotech | 208 | 1 |
| XuanZhu Pharma Co., Ltd. | 209 | 1 |
| Zymeworks Inc. | 210 | 1 |
| Gastric Cancer Therapeutics Assessment | 211 | 30 |
| Assessment by Monotherapy Products | 211 | 1 |
| Assessment by Combination Products | 212 | 1 |
| Assessment by Target | 213 | 12 |
| Assessment by Mechanism of Action | 225 | 12 |
| Assessment by Route of Administration | 237 | 2 |
| Assessment by Molecule Type | 239 | 2 |
| Drug Profiles | 241 | 697 |
| (calcium folinate + gimeracil + oteracil + tegafur) Drug Profile | 241 | 1 |
| (HM30181A + paclitaxel) Drug Profile | 242 | 3 |
| (tipiracil hydrochloride + trifluridine) Drug Profile | 245 | 6 |
| Pb-TCMC-Trastuzumab Drug Profile | 251 | 2 |
| AbGn-107 Drug Profile | 253 | 1 |
| AbGn-110 Drug Profile | 254 | 1 |
| AC-101 Drug Profile | 255 | 1 |
| AC-104 Drug Profile | 256 | 1 |
| ADCT-502 Drug Profile | 257 | 1 |
| ADXS-HER2 Drug Profile | 258 | 4 |
| afatinib dimaleate Drug Profile | 262 | 13 |
| afuresertib hydrochloride Drug Profile | 275 | 3 |
| AL-2846 Drug Profile | 278 | 1 |
| AL-3818 Drug Profile | 279 | 2 |
| ALM-301 Drug Profile | 281 | 1 |
| alpelisib Drug Profile | 282 | 3 |
| altiratinib Drug Profile | 285 | 2 |
| AMG-337 Drug Profile | 287 | 2 |
| apatinib Drug Profile | 289 | 3 |
| APV-224 Drug Profile | 292 | 1 |
| ARGX-111 Drug Profile | 293 | 2 |
| ARX-788 Drug Profile | 295 | 1 |
| ASN-004 Drug Profile | 296 | 1 |
| atezolizumab Drug Profile | 297 | 14 |
| avelumab Drug Profile | 311 | 6 |
| AZD-0156 Drug Profile | 317 | 1 |
| AZD-3965 Drug Profile | 318 | 2 |
| AZD-4547 Drug Profile | 320 | 2 |
| BAL-101553 Drug Profile | 322 | 5 |
| BAY-1143572 Drug Profile | 327 | 1 |
| BGB-290 Drug Profile | 328 | 2 |
| Biosimilar for Metastatic Breast Cancer and Gastric Cancer Drug Profile | 330 | 1 |
| BMS-777607 Drug Profile | 331 | 2 |
| BMS-936559 Drug Profile | 333 | 2 |
| BMS-986016 Drug Profile | 335 | 2 |
| BMS-986148 Drug Profile | 337 | 1 |
| BMS-986186 Drug Profile | 338 | 2 |
| BPI-9016 Drug Profile | 340 | 1 |
| brontictuzumab Drug Profile | 341 | 3 |
| cabazitaxel Drug Profile | 344 | 2 |
| cabazitaxel Drug Profile | 346 | 1 |
| Cantrixil Drug Profile | 347 | 3 |
| CB-1158 Drug Profile | 350 | 2 |
| CDX-1401 Drug Profile | 352 | 3 |
| CE-355621 Drug Profile | 355 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 356 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 357 | 1 |
| Cellular Immunotherapy for Solid Tumor and Central Nervous System Disorders Drug Profile | 358 | 1 |
| Cellular Immunotherapy to Taregt HER-2 for Oncology Drug Profile | 359 | 1 |
| Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology Drug Profile | 360 | 1 |
| Cellular Immunotherapy to Target CEA for Oncology Drug Profile | 361 | 1 |
| Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology Drug Profile | 362 | 1 |
| Cellular Immunotherapy to Target MUC1 for Gastric Cancer Drug Profile | 363 | 1 |
| Cellular Immunotherapy to Target MUC1 for Oncology Drug Profile | 364 | 1 |
| Cellular Immunotherapy to Target MUC1 for Solid Tumors Drug Profile | 365 | 1 |
| Cellular Immunotherapy to Target NY-ESO-1 for Oncology Drug Profile | 366 | 1 |
| Cellular Immunotherapy to Target Wilm's Tumor 1 for Oncology Drug Profile | 367 | 1 |
| cetuximab biobetter Drug Profile | 368 | 2 |
| CGX-1321 Drug Profile | 370 | 1 |
| CM-118 Drug Profile | 371 | 1 |
| CM-24 Drug Profile | 372 | 2 |
| CPL-043 Drug Profile | 374 | 1 |
| crizotinib Drug Profile | 375 | 7 |
| CRLX-101 Drug Profile | 382 | 11 |
| CS-2164 Drug Profile | 393 | 1 |
| CS-410 Drug Profile | 394 | 1 |
| CSG-002 Drug Profile | 395 | 1 |
| CV-02 Drug Profile | 396 | 1 |
| CV-04 Drug Profile | 397 | 1 |
| CV-05 Drug Profile | 398 | 1 |
| Debio-1347 Drug Profile | 399 | 2 |
| DFP-10825 Drug Profile | 401 | 1 |
| docetaxel Drug Profile | 402 | 2 |
| donafenib Drug Profile | 404 | 1 |
| doxorubicin Drug Profile | 405 | 1 |
| DS-8201 Drug Profile | 406 | 1 |
| durvalumab Drug Profile | 407 | 11 |
| durvalumab + tremelimumab Drug Profile | 418 | 4 |
| E1-3s Drug Profile | 422 | 1 |
| EF-022 Drug Profile | 423 | 1 |
| eflornithine hydrochloride Drug Profile | 424 | 2 |
| elgemtumab Drug Profile | 426 | 2 |
| emactuzumab Drug Profile | 428 | 1 |
| emibetuzumab Drug Profile | 429 | 2 |
| EP-400 Drug Profile | 431 | 1 |